SCHEMBL21843565

SCHEMBL21843565

CC(C)N1CCN(Cc2ccc(NC(=O)c3cncc(C#Cc4cnc5cccnn45)c3)cc2C(F)(F)F)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 13/20 0.73
▸ RET P07949 4/20 0.66
▸ ABL2 P42684 3/20 0.66
▸ FGFR1 P11362 3/20 0.66
▸ KDR P35968 3/20 0.66
▸ MAPK14 Q16539 2/20 0.66
▸ CCDC6 Q16204 2/20 0.66
▸ GAK O14976 1/20 0.66
▸ MLNR O43193 1/20 0.66
▸ RIPK2 O43353 1/20 0.66
▸ JAK2 O60674 1/20 0.66
▸ NR1I2 O75469 1/20 0.66
▸ ABCB11 O95342 1/20 0.66
▸ MAP4K4 O95819 1/20 0.66
▸ EGFR P00533 1/20 0.66
▸ NR3C1 P04150 1/20 0.66
▸ ERBB2 P04626 1/20 0.66
▸ NTRK1 P04629 1/20 0.66
▸ LCK P06239 1/20 0.66
▸ FYN P06241 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31474784 0.92 ABL1 (0.85) ABL1RETABL2FGFR1KDR
SCHEMBL24283388 0.92 ABL1 (0.77) ABL1RETABL2FGFR1KDR
SCHEMBL21843568 0.92 ABL1 (0.85) ABL1RETABL2FGFR1KDR
SCHEMBL21843637 0.92 ABL1 (0.75) ABL1RETABL2FGFR1KDR
SCHEMBL21843529 0.92 ABL1 (0.75) ABL1RETABL2FGFR1KDR
SCHEMBL21843567 0.91 ABL1 (0.74) ABL1RETABL2FGFR1KDR
SCHEMBL24283220 0.91 ABL1 (0.74) ABL1RETABL2FGFR1KDR
SCHEMBL24283386 0.90 ABL1 (0.76) ABL1RETABL2FGFR1KDR
SCHEMBL21843533 0.90 ABL1 (0.81) ABL1RETABL2FGFR1KDR
SCHEMBL21843569 0.90 ABL1 (0.73) ABL1RETABL2FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089599-A1 ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS PURDUE RESEARCH FOUNDATION 2022-03-24 — — US disclosed
WO-2020053812-A1 ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS PURDUE RESEARCH FOUNDATION (US) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089599-A1 ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS NADK, NAMPT, NME2 ABL1 22/4885RET 183/4885ABL2 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback